▶ CEREBROLYSIN · SUBTOPIC · DOSING LITERATURE

CEREBROLYSIN Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of CEREBROLYSIN. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for CEREBROLYSIN reports the following route(s) of administration: Intramuscular (clinical), Intravenous (clinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of CEREBROLYSIN.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for CEREBROLYSIN of approximately Variable (peptide mixture). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of CEREBROLYSIN. Refer to the original publication for full protocol detail.

Muresanu DF, Heiss WD, Hoemberg V, et al. (2016) reports the CEREBROLYSIN protocol used in Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial, published in Stroke. PMID 26786114. See the source for the protocol-level dose range, frequency, and duration. link
Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D (2018) reports the CEREBROLYSIN protocol used in Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials, published in Neurol Sci. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ How is Cerebrolysin administered?

Cerebrolysin is supplied as a ready-to-use solution in ampoules and administered by intramuscular or intravenous injection. Typical clinical courses are 10-30 mL daily for 10-21 days, with cycles repeated as clinically indicated. This wiki reproduces clinical dose ranges; any human use should be under qualified medical supervision.

▶ Is Cerebrolysin safe?

Published safety data across decades of European clinical use describes generally good tolerability with mild injection-site reactions, headache, and rare hypersensitivity reactions as the most common adverse events. Severe renal impairment and status epilepticus are contraindications.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · Room temperature in original ampoules

Reconstituted · n/a · supplied as ready-to-use solution

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Marketed by EVER Neuro Pharma in 50+ countries (Europe, Asia, Latin America) for stroke recovery, TBI, and vascular dementia. Research-use only in the United States.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ CEREBROLYSIN OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-25